Adverse effects: acne · minimal change disease in adults with nephrotic syndrome
Calcineurin inhibitors ± oral steroids may leads to lower adverse effects: acne compared with oral steroids alone (low certainty).
1 finding from 1 review
Primary: investigator‐rated good/excellent control of symptoms · people with moderate to severe chronic relapsing dyshidrotic eczema on hands
The review found no eligible studies for this question.
1 finding from 1 review
Primary: participant‐rated good/excellent control of symptoms Not measured · people with moderate to severe chronic relapsing dyshidrotic eczema on hands
The review found no eligible studies for this question.
1 finding from 1 review
Primary outcome 3: Adverse events · people with moderate to severe chronic relapsing dyshidrotic eczema on hands
1 finding from 1 review
Secondary: investigator‐rated reduction in severity ‐ DASIb · people with moderate to severe chronic relapsing dyshidrotic eczema on hands
1 finding from 1 review
Primary: investigator‐rated good/excellent control of symptoms · people with moderate to severe nickel sulphate‐induced allergic contact dermatitis based on clinical history (hand eczema) and proven by…
Topical calcineurin inhibitors: tacrolimus 0.1% ointment probably leads to higher primary: investigator‐rated good/excellent control of symptoms compared with vehicle (moderate certainty).
1 finding from 1 review
Primary: participant‐rated good/excellent control of symptoms Not measured · people with moderate to severe nickel sulphate‐induced allergic contact dermatitis based on clinical history (hand eczema) and proven by…
The review found no eligible studies for this question.
1 finding from 1 review
Primary: adverse events ‐ burning/itching at application site · people with moderate to severe nickel sulphate‐induced allergic contact dermatitis based on clinical history (hand eczema) and proven by…
Topical calcineurin inhibitors: tacrolimus 0.1% ointment showed no clear difference in primary: adverse events ‐ burning/itching at application site compared with vehicle (moderate certainty).
1 finding from 1 review
Secondary: investigator‐rated reduction in severity ‐ Not measured · people with moderate to severe nickel sulphate‐induced allergic contact dermatitis based on clinical history (hand eczema) and proven by…
The review found no eligible studies for this question.
1 finding from 1 review
Calcineurin inhibitor VAS(0 to 10 cm) · uraemic pruritus
1 finding from 1 review
Outcomes (up to 2 years for primary outcomes) · primary immunosuppression in kidney transplant recipients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
New onset of diabetes · primary immunosuppression in kidney transplant recipients
Target of rapamycin inhibitors (TOR‐I) showed no clear difference in new‐onset diabetes mellitus compared with calcineurin inhibitors (CNI): secondary outcomes (moderate certainty).
1 finding from 1 review
Lymphoma/PTLD · primary immunosuppression in kidney transplant recipients
Target of rapamycin inhibitors (TOR‐I) showed no clear difference in lymphoma/PTLD compared with calcineurin inhibitors (CNI): secondary outcomes (moderate certainty).
1 finding from 1 review
Tremor · primary immunosuppression in kidney transplant recipients
Target of rapamycin inhibitors (TOR‐I) leads to lower tremor compared with calcineurin inhibitors (CNI): secondary outcomes (high certainty).
1 finding from 1 review
GFR · primary immunosuppression in kidney transplant recipients
1 finding from 1 review
Cholesterol mg/dL · primary immunosuppression in kidney transplant recipients
1 finding from 1 review
Serum fasting triglyceride (TG, mmol/L) · primary immunosuppression in kidney transplant recipients
1 finding from 1 review
Thrombocytopenia · primary immunosuppression in kidney transplant recipients
Target of rapamycin inhibitors (TOR‐I) may leads to higher thrombocytopenia compared with calcineurin inhibitors (CNI): secondary outcomes (low certainty).
1 finding from 1 review
Death (all causes) · primary immunosuppression in kidney transplant recipients
Target of rapamycin inhibitors (TOR‐I) showed no clear difference in death (all causes) compared with calcineurin inhibitors (CNI): main outcomes (moderate certainty).
1 finding from 1 review
Graft loss censored for death · primary immunosuppression in kidney transplant recipients
Target of rapamycin inhibitors (TOR‐I) showed no clear difference in graft loss censored for death compared with calcineurin inhibitors (CNI): main outcomes (moderate certainty).
1 finding from 1 review